At A Glance
- ARA-290, also called cibinetide, is a short peptide designed from part of erythropoietin’s structure. Its research goal is to explore tissue-response signalling separately from EPO’s familiar red-blood-cell role.
- Phase 2 work reported changes in selected symptoms and nerve measures.
- ARA-290 was developed to explore tissue responses without erythropoiesis.
What Is ARA-290?
ARA-290, also called cibinetide, is a short peptide designed from part of erythropoietin’s structure. Its research goal is to explore tissue-response signalling separately from EPO’s familiar red-blood-cell role.
The proposed mechanism involves a receptor complex associated with repair-related signals rather than the classic red-cell-production pathway. That separation is what makes the design interesting.
Why Does ARA-290 Come Up In Nerve Research?
Small studies have explored it in small-fibre neuropathy, a condition involving the small nerves that carry sensations and other signals. Researchers measured selected symptoms and nerve-related outcomes.
Is It A Smaller Version Of EPO With The Same Effects?
It is a structural mimic designed around a different research question. EPO’s established red-cell effects therefore do not explain everything about ARA-290. The useful comparison is whether tissue-related activity can be explored without driving red-cell production.
A Closer Look At ARA-290
Here are the key observations and the context that helps explain them. The original sources are linked below if you would like to explore further.
| Study or context | What was explored | What it tells us | Useful context |
|---|---|---|---|
| Small human trials | Sarcoidosis-associated small-fibre neuropathy | Phase 2 work reported changes in selected symptoms and nerve measures. | These were small, specific clinical studies. |
| Design | Separating two signalling roles | ARA-290 was developed to explore tissue responses without erythropoiesis. | That design goal is different from supplying full EPO. |
Common Questions About ARA-290
What is ARA-290?+
ARA-290, also called cibinetide, is a short peptide designed from part of erythropoietin’s structure. Its research goal is to explore tissue-response signalling separately from EPO’s familiar red-blood-cell role.
Why does ARA-290 come up in nerve research?+
Small studies have explored it in small-fibre neuropathy, a condition involving the small nerves that carry sensations and other signals. Researchers measured selected symptoms and nerve-related outcomes.
Is it a smaller version of EPO with the same effects?+
It is a structural mimic designed around a different research question. EPO’s established red-cell effects therefore do not explain everything about ARA-290. The useful comparison is whether tissue-related activity can be explored without driving red-cell production.
Sources
Want to go a little deeper? These links take you to the studies and official records behind the guide. Study registries describe the plan; published papers report the findings.
- ARA 290 in sarcoidosis-associated small-fibre neuropathyPubMed-indexed early human study · 2013
Small early human study with selected symptom and nerve endpoints. Sample size, indication, formulation, and replication limit broader conclusions.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
For ARA-290 context, this official Canadian advisory explains why a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote For ARA-290
This compound is not currently stocked. Add it to your five-choice catalogue ballot.